Patient Leaflet Updated 27-Oct-2025 | Gilead Sciences Ltd
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead 150mg/150mg/200mg/10mg film coated tablets
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead® 150 mg/150 mg/200 mg/10 mg film-coated tablets
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead® 90 mg/90 mg/120 mg/6 mg film-coated tablets
1. What Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead is and what it is used for
2. What you need to know before you take Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead
3. How to take Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead
4. Possible side effects
5. How to store Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead
6. Contents of the pack and other information
If Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead has been prescribed for your child, please note that all the information in this leaflet is addressed to your child (in this case please read “your child” instead of “you”).
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead contains four active substances:
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead is a single tablet for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults, adolescents and children 2 years of age and older, who weigh at least 14 kg.
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead reduces the amount of HIV in your body. This will improve your immune system and reduce the risk of developing illnesses linked to HIV infection.
You must remain under the care of your doctor while taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead.
This medicine is not a cure for HIV infection. While taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead you may still develop infections or other illnesses associated with HIV infection.
Talk to your doctor before taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead:
Once you start taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead, look out for:
There is a possibility that you may experience kidney problems when taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead over a long period of time (see Warnings and precautions).
Do not give this medicine to children under 2 years of age, or weighing less than 14 kg regardless of age. The use of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead in children under 2 years of age, or weighing less than 14 kg has not yet been studied.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead may interact with other medicines. As a result, the amounts of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead or other medicines in your blood may be affected. This may stop your medicines from working properly, or may make any side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.
Medicines that must never be taken with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead:
Medicines used in treating hepatitis B infection:
You should not take Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead with medicines containing:
Talk to your doctor if you are taking:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead can cause dizziness. If you feel dizzy when taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead, do not drive or ride a bicycle and do not use any tools or machines.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
There are two strengths of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead tablets. Your doctor will prescribe the appropriate tablet for your age and weight.
Adults, adolescents and children who weigh at least 25 kg: one tablet each day with food (one 150 mg/150 mg/200 mg/10 mg tablet)
Children 2 years of age and older, who weigh at least 14 kg but less than 25 kg: one tablet each day with food (one 90 mg/90 mg/120 mg/6 mg tablet)
Due to the bitter taste, it is recommended not to chew or crush the tablet.
If you have difficulty swallowing the tablet whole, you can split it in half. Take both halves of the tablet one after the other to get the full dose. Do not store the split tablet.
The score line on the 90 mg/90 mg/120 mg/6 mg tablet is only there to help you break the tablet if your child has difficulty swallowing it whole.
Always take the dose recommended by your doctor. This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.
Do not take antacids or multivitamins at the same time as Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead. If you are taking medicines, oral supplements, antacids or laxatives containing minerals (such as magnesium, aluminium, calcium, iron, zinc), take them at least 4 hours before or at least 4 hours after Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead.
If you are on dialysis, take your daily dose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead following completion of dialysis.
If you accidentally take more than the recommended dose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects).
Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.
It is important not to miss a dose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead.
If you do miss a dose:
If you vomit less than 1 hour after taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead, take another tablet with food.
Do not stop taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead without talking to your doctor. Stopping Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead can seriously affect your response to future treatment. If Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead is stopped for any reason, speak to your doctor before you restart taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead tablets.
When your supply of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead starts to run low, get more from your doctor or pharmacist. This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. The disease may then become harder to treat.
If you have both HIV infection and hepatitis B, it is especially important not to stop your Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead treatment without talking to your doctor first. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common side effects
(may affect more than 1 in 10 people)
Common side effects
(may affect up to 1 in 10 people)
Uncommon side effects
(may affect up to 1 in 100 people)
The frequency of the following side effects is not known (frequency cannot be estimated from the available data).
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle after {EXP}. The expiry date refers to the last day of that month.
Store in the original package in order to protect from moisture. Keep the bottle tightly closed.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substances are elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.
The other ingredients are
Tablet core:
Lactose (as monohydrate), microcrystalline cellulose (E460), croscarmellose sodium, hydroxypropyl cellulose (E463), silicon dioxide (E551), sodium lauryl sulfate, magnesium stearate.
Film-coating:
Polyvinyl alcohol (E1203), titanium dioxide (E171), polyethylene glycol (E1521), talc (E553b), iron oxide yellow (E172), indigo carmine aluminium lake (E132 - 150 mg/150 mg/200 mg/10 mg tablet only), iron oxide black (E172 - 90 mg/90 mg/120 mg/6 mg tablet only).
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead 150 mg/150 mg/200 mg/10 mg film-coated tablets are green, capsule-shaped tablets, debossed on one side with “GSI” and the number “510” on the other side of the tablet.
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead 90 mg/90 mg/120 mg/6 mg film-coated tablets are green, capsule-shaped tablets, debossed on one side with “GSI” and scored on the other side of the tablet.
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Gilead comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets). The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in 08/2025.
SZ006
280 High Holborn, London, WC1V 7EE, UK
+44 (0)203 681 4681
08000 113 700 (UK)
+44 (0)203 681 4500
+353 1 291 3580 (Ireland)
+353 214 825 999 (Ireland)